Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial
Principal Investigator
Michael Vogelbaum, MD, PhD
Status
Terminated
Date Opened To Accrual
July 22 2009
Date Closed to Accrual
September 16 2015
Date of Study Termination
August 12 2025
Disease Site
Brain [BN]
Benign Brain Tumors
Phase
III
Developmental Therapeutics
No
Primary Objective
Patient Population
-
Target Accrual
748
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.